Deneb Medical’s main achievement so far has been the development of the first version of the BONECUT prototype. This prototype has been tested in InVivo pigs with positive results. Further DENEB has achieved promising results using spectroscopic techniques for tissue identification. These data have been post-processed using DENEB’s proprietary algorithms for tissue identification and the results have been very good. These results are applicable both for BONECUT as well as for the MultiTissue CoBot. Next steps on this technique are its integration on BONECUT from an optical and control point of view and its testing on InVivo pig models. The MultiTissue CoBot will allow the surgeon to distinguish between nerves, blood vessels and other soft tissues, so that selective ablation in soft-tissue surgeries can be done. BONECUT will open up new surgical applications for DENEB’s CoBot: I.e. it will allow renal tumours to be removed by partial nephrectomy without ischemia or will reduce duration and bleeding in liver surgery. Amongst its numerous applications are major surgical disciplines such as urology, neurosurgery, liver surgery, cardiovascular etc. In the future BONECUT will be implemented both in open and endoscopic surgeries allowing new surgical approaches and techniques that cannot be performed today.
During 2018 DENEB has had an important impact and visibility on some relevant events in the medtech sector. DENEB was selected to participate in the Medtech Innovator Accelerator program set up by an organisation called “Medtech Innovator” (
https://medtechinnovator.org/(odnośnik otworzy się w nowym oknie)) located in Los Angeles and funded by the medtech industry’s big industrial players, such as Johnson&Johnson, Baxter, Olympus, etc. The Medtech Innovator organises a yearly competition where more than 700 medtech start-ups worldwide compete to be selected to participate in the Medtech Innovator Accelerator program. Among the more than 700 participating companies DENEB was selected to pitch in front of a specialised jury formed by people working for the above mentioned big industrial corporations. DENEB pitched in April 2018 in an event held in Dublin and was among the four finalist companies of that event. A last selection of companies was done from the finalists of the different selection events held worldwide and DENEB was finally selected to be one of the 25 participants in the 2018 Medtech Innovator Accelerator program. DENEB’s participation in this exclusive program was an acknowledgement of the impact that BONECUT and the tissue differentiation technology will have once it is in the market.
The accelerator program consisted in an intensive 3-month work period where the participants were assigned mentors from the funding companies and had access to specialists in regulatory, market access, IP, healthcare economics, etc. The aim of the program is to do a 360º analysis of the project and correct, modify and focus each aspect of the project in order to move forward in the correct direction from the technology, product and market perspective. During the accelerator program DENEB was mentored by Johnson&Johnson and Olympus and established a very valuable relationship with those corporations.
Thanks to the Medtech Accelerator Program DENEB had the opportunity to meet relevant KOL surgeons, managers at the FDA’s medtech division and other relevant players in the industry. Additionally, the Medtech Innovator promoted DENEB’s project in social networks with information and interviews such as this one: Deneb Medical.
During 2018 DENEB was also selected to participate in a program called Bind 4.0 (
https://bind40.com/(odnośnik otworzy się w nowym oknie)) held in the Basque Country (Spain) with the aim of promoting the sale to established companies of innovative products developed by start-ups. In Bind 4.0 an established company “binds” to a start-up he is interested to collaborate with because of its technology or its products. Keralty (
https://www.keralty.com/en/web/guest/home(odnośnik otworzy się w nowym oknie)) an international healthcare group with hospitals in the USA, Colombia and other parts of the world, selected DENEB and both companies are currently working on a collaboration agreement that may end up with the supply of BONECUT systems to be used at Keralty’s hospitals.
Last, the following media have published information with regard to Deneb's Project:
1.- The prestigious American magazine “The Silicon Review” (
https://thesiliconreview.com/about-us(odnośnik otworzy się w nowym oknie)) published an article about DENEB in 2018 (
https://thesiliconreview.com/magazines/the-robotic-platform-developers-deneb-medical-is-the-brightest-star-in-the-medtech-industry/(odnośnik otworzy się w nowym oknie)). The Silicon Review is the world’s most trusted online and print community for business & technology professionals. According to their website their “community members include thought-provoking CEOs, CIOs, CTOs, IT VPs and managers, along with jillions of diverse business professionals”. The publication of the article by such an important business and technology magazine was another big acknowledgement to DENEB’s technology and product.
2.- The Medical Device and Diagnostic Industry published an article titled “The 25 Medtech Startups You Need to Know”, where they provide a list of 25 companies that could have a huge impact on the healthcare industry. DENEB is one of those 25 companies in the list:
https://www.mddionline.com/25-medtech-startups-you-need-know?ADTRK=UBM&elq_mid=6109&elq_cid=917766(odnośnik otworzy się w nowym oknie)3.- Medtech Innovator promoted DENEB’s project in social networks with information and interviews such as this one:
https://www.medtechstrategist.com/mts-blog/interview-deneb(odnośnik otworzy się w nowym oknie)
